Advanced

Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease : Elevated oxidized low-density lipoprotein and the anti-inflammatory effect of artorvastatin

Grip, Olof LU ; Janciauskiene, Sabina LU and Lindgren, Stefan LU (2004) In Inflammatory Bowel Diseases 10(3). p.193-200
Abstract

We investigated inflammatory biomarkers in plasma and in circulating monocytes obtained from patients with Crohn's disease and healthy individuals. Additionally, we assessed the effects of atorvastatin, 10 μM, ex vivo on monocytes cultured for 18 hours from the same subjects. Plasma and blood monocytes from eight patients with active Crohn's disease and eight healthy individuals were analyzed by enzyme-linked immunosorbent and electrophoretic mobility assays. Patients with active Crohn's disease had increased plasma levels of tumor necrosis factor (TNF)-α (7.7-fold;p < 0.05), monocyte chemoattractant protein (MCP)-1 (1.3-fold; p < 0.05), and oxidized low density lipoprotein (oxLDL) (1.2-fold; p < 0.05). Monocytes from patients... (More)

We investigated inflammatory biomarkers in plasma and in circulating monocytes obtained from patients with Crohn's disease and healthy individuals. Additionally, we assessed the effects of atorvastatin, 10 μM, ex vivo on monocytes cultured for 18 hours from the same subjects. Plasma and blood monocytes from eight patients with active Crohn's disease and eight healthy individuals were analyzed by enzyme-linked immunosorbent and electrophoretic mobility assays. Patients with active Crohn's disease had increased plasma levels of tumor necrosis factor (TNF)-α (7.7-fold;p < 0.05), monocyte chemoattractant protein (MCP)-1 (1.3-fold; p < 0.05), and oxidized low density lipoprotein (oxLDL) (1.2-fold; p < 0.05). Monocytes from patients with Crohn's disease showed enhanced secretion of MCP-1 (4.8-fold; p < 0.05) and a markedly suppressed secretion of macrophage migration inhibitory factor (MIF) (93%; p < 0.001). Transcriptional activation of nuclear factor-kappaB did not differ between the groups. Treating monocytes with atorvastatin resulted in the suppression of MCP-1 (42%; p < 0.05) and TNF-α (45%; p < 0.05) secretion. These results show increased levels of certain proinflammatory biomarkers, including oxLDL, in plasma and indicate that peripheral blood monocytes in active Crohn's disease are sensitized to chemotaxis. Treatment with atorvastatin may be a potential strategy to reduce oxLDL and inhibit monocyte migration to inflamed tissue, thus attenuating the inflammatory response.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Atorvastatin, Crohn's disease, Inflammation, Monocytes
in
Inflammatory Bowel Diseases
volume
10
issue
3
pages
8 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:2442445373
ISSN
1078-0998
DOI
10.1097/00054725-200405000-00003
language
English
LU publication?
yes
id
f916995f-9b9a-4693-aee4-0ff3ceaca5b7
date added to LUP
2019-08-07 13:28:52
date last changed
2019-08-16 14:06:32
@article{f916995f-9b9a-4693-aee4-0ff3ceaca5b7,
  abstract     = {<p>We investigated inflammatory biomarkers in plasma and in circulating monocytes obtained from patients with Crohn's disease and healthy individuals. Additionally, we assessed the effects of atorvastatin, 10 μM, ex vivo on monocytes cultured for 18 hours from the same subjects. Plasma and blood monocytes from eight patients with active Crohn's disease and eight healthy individuals were analyzed by enzyme-linked immunosorbent and electrophoretic mobility assays. Patients with active Crohn's disease had increased plasma levels of tumor necrosis factor (TNF)-α (7.7-fold;p &lt; 0.05), monocyte chemoattractant protein (MCP)-1 (1.3-fold; p &lt; 0.05), and oxidized low density lipoprotein (oxLDL) (1.2-fold; p &lt; 0.05). Monocytes from patients with Crohn's disease showed enhanced secretion of MCP-1 (4.8-fold; p &lt; 0.05) and a markedly suppressed secretion of macrophage migration inhibitory factor (MIF) (93%; p &lt; 0.001). Transcriptional activation of nuclear factor-kappaB did not differ between the groups. Treating monocytes with atorvastatin resulted in the suppression of MCP-1 (42%; p &lt; 0.05) and TNF-α (45%; p &lt; 0.05) secretion. These results show increased levels of certain proinflammatory biomarkers, including oxLDL, in plasma and indicate that peripheral blood monocytes in active Crohn's disease are sensitized to chemotaxis. Treatment with atorvastatin may be a potential strategy to reduce oxLDL and inhibit monocyte migration to inflamed tissue, thus attenuating the inflammatory response.</p>},
  author       = {Grip, Olof and Janciauskiene, Sabina and Lindgren, Stefan},
  issn         = {1078-0998},
  keyword      = {Atorvastatin,Crohn's disease,Inflammation,Monocytes},
  language     = {eng},
  month        = {05},
  number       = {3},
  pages        = {193--200},
  publisher    = {John Wiley & Sons},
  series       = {Inflammatory Bowel Diseases},
  title        = {Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease : Elevated oxidized low-density lipoprotein and the anti-inflammatory effect of artorvastatin},
  url          = {http://dx.doi.org/10.1097/00054725-200405000-00003},
  volume       = {10},
  year         = {2004},
}